Biotech Breakouts, Bold Deals, and a Spider Silk Revolution

DENVER, Colo., Oct 20, 2025 (247marketnews.com)- Wall Street is buzzing this Friday as a mix of innovative biotech breakthroughs, next-gen partnerships, and surprising revenue beats drive a midday rally across select sectors. Here’s your editorial roundup of today’s top stories:

Kraig Biocraft Laboratories (OTCQB:KBLB) launched its sixth spider silk production cycle of 2025 and debuted BAM-1 Alpha, the latest version of its recombinant spider silk platform. Touted as “a major leap forward,” the BAM-1 Alpha fiber offers higher yields, with no infrastructure upgrades required, setting the stage for seamless scaling.

CEO Kim Thompson called the launch “an exhilarating moment,” emphasizing that BAM-1 Alpha represents years of “focused innovation.” As the world leans into sustainable super fibers, KBLB continues to position itself as a key player at the cutting edge of advanced biomaterials.

Celcuity (NASDAQ:CELC) is surging after presenting compelling Phase 3 results for gedatolisib at ESMO. The drug reduced disease progression by up to 76% in certain PIK3CA wild-type HR+/HER2- breast cancer cohorts. With fewer than 10% experiencing hyperglycemia and a strong safety profile, momentum is building behind the therapy’s potential.

A rolling NDA submission is in progress, and new data from the PIK3CA-mutant population is expected in early 2026.

Beyond Meat (NASDAQ:BYND) found relief from a steep multi-week slide, bouncing midday on short-covering and speculative buying. While challenges remain — including margin pressure and declining revenue, the upcoming Q3 earnings report, falling input costs, and high options volume suggest traders are bracing for heightened volatility.

Caution remains the name of the game, but BYND is flashing signals as a high-beta contrarian play.

Azitra (NYSE:AZTR) is getting attention after unveiling preclinical data for its ATR-01 program targeting ichthyosis vulgaris, a rare skin condition affecting 1.3 million Americans. In ex vivo studies, the company’s genetically engineered S. epidermidis strain successfully delivered functional human filaggrin through the skin and showed significant reduction in water loss (p < 0.002).

CEO Francisco Salva highlighted the treatment’s potential to “address the root cause” of the disease. First-in-human trials are being eyed for 2026.

Rani Therapeutics (NASDAQ:RANI) soared after announcing a major partnership with Chugai Pharmaceutical Co., Ltd. to co-develop an oral antibody therapy using Rani’s RaniPill platform. The deal includes a $10 million upfront payment, up to $175 million in milestones for the first product, and potential for $1.085 billion if Chugai extends to five more drug targets.

CEO Talat Imran emphasized the opportunity to reduce treatment burden by replacing injectables with oral formulations, calling the partnership a move toward “advanced, patient-centric healthcare.”

Alto Neuroscience (NYSE:ANRO) is pushing forward with its pipeline of precision neuropsychiatric drugs after a successful FDA meeting cleared the path for ALTO-207, aimed at treatment-resistant depression. Backed by a $50 million private placement, Alto plans to initiate a Phase 3 trial by early 2027.

Positive pharmacokinetic data from ongoing studies of ALTO-100 and ALTO-101 also supports trial compliance and tolerability. CEO Dr. Amit Etkin said  thatAlto is well-positioned to advance ALTO-207 for the many patients not adequately served by current therapies.

Citius Oncology (NASDAQ:CTOR), a unit of Citius Pharmaceuticals (NASDAQ:CTXR), signed a U.S. distribution agreement with McKesson Corporation (NYSE:MCK) for its recently approved LYMPHIR immunotherapy, aimed at refractory Stage I–III cutaneous T-cell lymphoma (CTCL).

With all three major U.S. distributors now on board, commercial launch is expected in Q 2025. CEO Leonard Mazur says the deal reflects a deep commitment to ensuring timely access” for patients and providers.

CorMedix (NASDAQ:CRMD) posted preliminary Q3 2025 net revenue over $125 million, driven by strong uptake of DefenCath, which alone generated $85 million+. The company raised its full-year revenue guidance to at least $375 million, up from $350 million, citing better-than-expected performance across its portfolio and synergies from its Melinta acquisition.

Adjusted EBITDA is projected at $70 million+, and Q3 integration synergies are already contributing $30 million in cost savings. The pipeline remains active with a Phase 3 study of Rezzayo™ on track to report data in Q2 2026.

For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, CELC, BYND, AZTR, RANI, CRMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.